1. A Multicenter Evaluation of Treatment-associated Changes in Body Composition in Men With Germ Cell Tumors of the Testis: Implications for Adverse Events and Complications.
- Author
-
Buxton C, Schmeusser BN, Holt SK, Patil D, Phuong A, Chahine S, Marquardt JP, O'Malley R, Laidlaw G, Schade GR, Lin DW, Schweizer MT, Yezefski T, Yu EY, Montgomery B, Fintelmann FJ, Master VA, and Psutka SP
- Subjects
- Humans, Male, Retrospective Studies, Adult, Lymph Node Excision adverse effects, Cisplatin adverse effects, Cisplatin administration & dosage, Postoperative Complications epidemiology, Postoperative Complications etiology, Young Adult, Middle Aged, Antineoplastic Agents adverse effects, Testicular Neoplasms drug therapy, Testicular Neoplasms surgery, Neoplasms, Germ Cell and Embryonal drug therapy, Body Composition
- Abstract
Objective: To characterize changes in body composition following cytotoxic chemotherapy for germ cell carcinoma of the testis (GCT) and quantify associations between body composition metrics and chemotherapy-associated adverse events (AEs) and post-retroperitoneal lymph node dissection (RPLND) complications., Materials and Methods: This retrospective multi-center study included 216 men with GCT treated with cytotoxic chemotherapy and/or RPLND (2005-2020). We measured body composition including skeletal muscle (SMI), visceral adipose (VAI,), subcutaneous adipose (SAI), and fat mass (FMI) indices on computed tomography. We quantified chemotherapy-associated changes in body composition and evaluated associations between body composition and incidence of grade 3 + AEs and post-RPLND complications on multivariable logistic regression analyses., Results: One hundred and eighty-two men received a median of 3 cycles of cisplatin-based chemotherapy. Following chemotherapy, median change in SMI was -6% (P = <.0001), while VAI, SAI, and FMI increased by +13% (P = <.0001), +11% (P = <.0001), and +6% (P = <.0001), respectively. Seventy-nine patients (43%) experienced at least one grade 3 + AE. A decrease in SMI following chemotherapy was associated with increased risk of grade 3 + AEs (P = .047). One hundred and 3 men with a median age of 28.5 years (IQR 23-35.5) underwent RPLND of whom 22 (21.3%) experienced at least 1 grade 3 + post-RPLND complication. No baseline body composition metrics were associated with post-RPLND complications., Conclusion: In men with GCT of the testis, chemotherapy was associated with 6% loss of lean muscle mass and gains in adiposity. Lower skeletal muscle was associated with a higher incidence of chemotherapy-associated AEs. Body composition was not associated with the incidence of post-RPLND complications., Competing Interests: Declaration of Competing Interest Sarah Psutka serves on an advisory board for Janssen/Johnson & Johnson, Immunity Bio, CG Oncology, Merck; Research funded by the National Institute on Aging, the Bladder Cancer Advocacy Network; Global PI for SunRISE-4; Janssen; Florian Fintelmann receives research support from Pfizer, serves as a consultant and speaker for Boston Scientific, and has a patent for “patient risk stratification based on body composition derived from computed tomography images sing machine learning” (patent number: WO2019051358A1). The remaining authors declare that they have no conflict of interest., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF